![Foto de Bruno Carlos](/img/uploaded/6B445665F8CF9B93F87A62EA31963C07.png)
Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Publicacións (430) Publicacións de Bruno Carlos Sangro Gómez-Acebo
2024
-
Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies
CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
From the Editor's Desk
Journal of hepatology, Vol. 80, Núm. 2, pp. 173-175
-
From the Editor's Desk.
Journal of Hepatology
-
From the Editor's Desk.
Journal of Hepatology
-
From the Editor's Desk...
Journal of Hepatology
-
From the Editor's Desk...
Journal of Hepatology
-
From the Editor's Desk…
Journal of Hepatology
-
Himalaya Overall Survival Prominence and Other Routes to the Peak
JAMA Oncology
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
JHEP Reports, Vol. 6, Núm. 4
-
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190
-
The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies
Annals of Surgery, Vol. 280, Núm. 1, pp. 46-55
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343
-
Combination immunotherapy for hepatocellular carcinoma
Journal of Hepatology, Vol. 79, Núm. 2, pp. 506-515